PDCD1 and neoplasm: Since most patients with advanced NSCLC lose the opportunity for surgical resection, they often require anti-tumor immunotherapy, such as anti-programmed cell death-1 (PD-1) immunotherapy (Shepherd, Douillard & Blumenschein, 2011).